Download PDF
Drug Res (Stuttg) 2021; 71(01): 4-9
DOI: 10.1055/a-1274-1264
Original Article

Tutankhamun’s Antimalarial Drug for Covid-19

Andrei P. Sommer
1   Faculty of Science, ISRA University, Amman
,
Horst-Dieter Försterling
2   Department of Chemistry, Philipps University Marburg, Marburg
,
Katlin E. Sommer
3   UWID Group, Bergische Universität, Wuppertal
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Drug repositioning is a strategy that identifies new uses of approved drugs to treat conditions different from their original purpose. Current efforts to treat Covid-19 are based on this strategy. The first drugs used in patients infected with SARS-CoV-2 were antimalarial drugs. It is their mechanism of action, i. e., rise in endosomal pH, which recommends them against the new coronavirus. Disregarding their side effects, the study of their antiviral activity provides valuable hints for the choice and design of drugs against SARS-CoV-2. One prominent drug candidate is thymoquinone, an antimalarial substance contained in Nigella sativa – most likely one of the first antimalarial drugs in human history. Since the outbreak of the pandemic, the number of articles relating thymoquinone to Covid-19 continuously increases. Here, we use it as an exemplary model drug, compare its antiviral mechanism with that of conventional antimalarial drugs and establish an irreducible parametric scheme for the identification of drugs with a potential in Covid-19.Translation into the laboratory is simple. Starting with the discovery of Nigella sativa seeds in the tomb of Pharaoh Tutankhamun, we establish a physicochemical model for the interaction of thymoquinone with both coronavirus and cells. Exploiting the predictive capability of the model, we provide a generalizable scheme for the systematic choice and design of drugs for Covid-19. An unexpected offshoot of our research is that Tutankhamun could not have died of malaria, a finding contrary to the mainstream theory.

Key words

coronavirus - SARS-CoV-2 - antiviral drugs - antibacterial drugs - anti-inflammatory drugs - antiparasitic drugs - biopharmaceuticals - drug repositioning - thymoquinone


Publication History

Received: 01 September 2020

Accepted: 28 September 2020

Article published online:
30 October 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Gholamnezhad Z, Havakhah S, Boskabady MH. Preclinical and clinical effects of Nigella sativa and its constituent, thymoquinone: A review. J Ethnopharmacol 2016; 190: 372-386
    CrossrefPubMedGoogle Scholar
  • 2 Rahmani AH, Aly SM. Nigella sativa and its active constituent thymoquinone shows pivotal role in the diseases prevention and treatment. Asian J Pharm. Clin Res 2015; 8: 48-53
    PubMedGoogle Scholar
  • 3 Ahmad A, Husain A, Mujeeb M. et al. A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed 2013; 3: 337-352
    CrossrefPubMedGoogle Scholar
  • 4 Sommer AP, Försterling HD, Naber KG. Thymoquinone: Shield and sword against SARS-CoV-2. Precis Nanomed 2020; 3: 541-548
    PubMedGoogle Scholar
  • 5 Savarino A, Boelaert JR, Cassone A. et al. Effects of chloroquine on viral infections: An old drug against today’s diseases?. Lancet Infect Dis 2003; 3: 722-727
    CrossrefPubMedGoogle Scholar
  • 6 Rathore C, Rathbone MJ, Chellappan DK. et al. Nanocarriers: More than tour de force for thymoquinone. Expert Opin Drug Deliv 2020; 17: 479-494
    CrossrefPubMedGoogle Scholar
  • 7 Liu C, Zhou Q, Li Y. et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Cent Sci 2020; 6: 315-331
    CrossrefPubMedGoogle Scholar
  • 8 Benavides CV. Drug repositioning for COVID-19. Colomb Med (Cali) 2020; 51: 1-11
    PubMedGoogle Scholar
  • 9 Wilford JN. Malaria is a likely killer in King Tut’s post-mortem. The New York Times. Feb. 16 2010
    Google Scholar
  • 10 Feachem RGA, Phillips AA, Hwang J. et al. Shrinking the malaria map: Progress and prospects. Lancet 2010; 376: 1566-1578
    CrossrefPubMedGoogle Scholar
  • 11 Timmann C, Meyer CG. Malaria, mummies, mutations: Tutankhamun's archaeological autopsy. Trop Med Int Health 2010; 15: 1278-1280
    CrossrefPubMedGoogle Scholar
  • 12 Hawass Z, Gad YZ, Ismail S. et al. Ancestry and pathology in King Tutankhamun's family. JAMA 2010; 303: 638-647
    CrossrefPubMedGoogle Scholar
  • 13 Hussein K, Matin E, Nerlich AG. Paleopathology of the juvenile Pharaoh Tutankhamun-90th anniversary of discovery. Virchows Arch 2013; 463: 475-479
    CrossrefPubMedGoogle Scholar
  • 14 http://www.griffith.ox.ac.uk/gri/4tutbot.html
  • 15 Fujisaki R, Kamei K, Yamamura M. et al. In vitro and in vivo anti-plasmodial activity of essential oils, including hinokitiol. Southeast Asian J Trop Med Public Health 2012; 43: 270-279
    PubMedGoogle Scholar
  • 16 Johnson-Ajinwo OR, Ullah I, Mbye H. et al. The synthesis and evaluation of thymoquinone analogues as anti-ovarian cancer and antimalarial agents. Bioorg Med Chem Lett 2018; 28: 1219-1222
    CrossrefPubMedGoogle Scholar
  • 17 Fröhlich T, Reiter C, Saeed MEM. et al. Synthesis of thymoquinone-artemisinin hybrids: New potent antileukemia, antiviral, and antimalarial agents. ACS Med Chem Lett 2017; 9: 534-539
    CrossrefPubMedGoogle Scholar
  • 18 Ahmed el-HM, Nour BY, Mohammed YG. et al. Antiplasmodial activity of some medicinal plants used in sudanese folk-medicine. Environ Health Insights 2010; 4: 1-6
    PubMed
  • 19 Abdulelah HAA, Zainal-Abidin BAH. In vivo antimalarial tests of Nigella sativa (black seed) different extracts. Am J Pharmacol Toxicol 2007; 2: 46-50
    CrossrefPubMedGoogle Scholar
  • 20 Ghafari S, Esmaeili S, Naghibi F. et al. Plants used to treat “tabe rebá” (malaria like fever) in Iranian traditional medicine. Intl J Trad Herb Med 2013; 1: 168-176
    PubMedGoogle Scholar
  • 21 Gabriel RA. Man and wound in the ancient world: A history of military medicine from Sumer to the fall of Constantinople. 1st ed. Potomac Books; 2012: 72
    CrossrefGoogle Scholar
  • 22 Sallam HN. Aristotle, godfather of evidence-based medicine. Facts Views Vis Obgyn 2010; 2: 11-19
    PubMedGoogle Scholar
  • 23 Ibraheem NK, Ahmed JH, Hassan MK. The effect of fixed oil and water extracts of Nigella Sativa on sickle sells: an in vitro study. Singapore Med J 2010; 51: 230-234
    PubMedGoogle Scholar
  • 24 Avicenna IS. Canon of Medicine. Kazi Publications, Inc., Chicago, Illinois, USA. 1999
    Google Scholar
  • 25 Islam M, Sultana N, Alam Riaz T. et al. Thymoquinone is knocking at the door of clinical trial. Int Arch Med 2016; 9: 1-25
    CrossrefPubMedGoogle Scholar
  • 26 https://www.mpg.de/14825271/artemisia-annua-artemisinin-coronavirus
  • 27 Esposito G, Pesce M, Seguella L. et al. The potential of cannabidiol in the COVID-19 pandemic. Br J Pharmacol. 2020 DOI: 10.1111/bph.15157
    Google Scholar
  • 28 Wang Y, Liu M, Gao J. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proc Natl Acad Sci USA 2020; 117: 13967-13974
    CrossrefPubMedGoogle Scholar
  • 29 Liu J, Cao R, Xu M. et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov 2020; 6: 16
    CrossrefPubMedGoogle Scholar
  • 30 Asaduzzaman Khan M, Tania M, Fu S, Fu J. Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget 2017; 8: 51907-51919
    CrossrefPubMedGoogle Scholar
  • 31 Ochsendorf FR. Use of antimalarials in dermatology. J Dtsch Dermatol Ges 2010; 8: 829-944
    CrossrefPubMedGoogle Scholar
  • 32 Salata C, Calistri A, Parolin C. et al. Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther 2017; 15: 483-492
    CrossrefPubMedGoogle Scholar
  • 33 Cairns DM, Rouleau N, Parker RN. et al. A 3D human brain-like tissue model of herpes-induced Alzheimer's disease. Sci Adv 2020; 6: eaay8828
    CrossrefPubMedGoogle Scholar
  • 34 Ezzat K, Pernemalm M, Pålsson S. et al. The viral protein corona directs viral pathogenesis and amyloid aggregation. Nat Commun 2019; 10: 2331
    CrossrefPubMedGoogle Scholar
  • 35 Isabel S, Graña-Miraglia L, Gutierrez JM. et al. Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide. Sci Rep 2020; 10: 14031
    CrossrefPubMedGoogle Scholar
  • 36 Kadil Y, Mouhcine M, Filali H. In silico investigation of the SARS CoV2 protease with thymoquinone major constituent of Nigella sativa. Curr Drug Discov Technol. 2020; doi: 10.2174/1570163817666200712164406
    Google Scholar
  • 37 Mohideen AKS. Molecular docking analysis of phytochemical thymoquinone as a therapeutic agent on SARS-Cov-2 envelope protein. Biointerface Res Appl Chem 2021; 11: 8389-8401
    PubMedGoogle Scholar
  • 38 Coppola M, Mondola R. Potential Unconventional Medicines for the Treatment of SARS-CoV-2. Drug Res (Stuttg) 2020; 70: 286
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 https://www.afro.who.int/news/expert-panel-endorses-protocol-covid-19-herbal-medicine-clinical-trials